Cannabis for Pain

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Pain+5 More
Cannabis - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test the effectiveness of three cannabis oil extract combinations (High THC-Low CBD, Low THC-High CBD, or Equal amounts of THC and CBD) in a minimum of 120 cancer patients on 4 cancer-related symptoms: nausea, pain, anxiety and sleep disturbance.

Eligible Conditions
  • Pain
  • Anxiety
  • Sleep Disturbance
  • Nausea

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 16-48 days; 90 minutes after each dose

16-48 days
Percent of subjects who prefer each study oil (Oil 1, 2, 3 or 4)
Day 48
Average Patients' Global Impression of Change (PGIC) for overall cancer-related symptoms
16-48 days; once daily
Average change from baseline in the Edmonton Symptom Assessment System - revised to include Sleep Disturbance and Night Sweats (ESAS-r-SN) score

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

4 Treatment Groups

Equal amounts of THC/CBD Cannabis Oil
1 of 4
High THC/Low CBD Cannabis Oil
1 of 4
Low THC/High CBD Cannabis Oil
1 of 4
Placebo Oil
1 of 4

Experimental Treatment

Non-Treatment Group

150 Total Participants · 4 Treatment Groups

Primary Treatment: Cannabis · Has Placebo Group · Phase 2

Equal amounts of THC/CBD Cannabis Oil
Drug
Experimental Group · 1 Intervention: Cannabis · Intervention Types: Drug
High THC/Low CBD Cannabis Oil
Drug
Experimental Group · 1 Intervention: Cannabis · Intervention Types: Drug
Low THC/High CBD Cannabis Oil
Drug
Experimental Group · 1 Intervention: Cannabis · Intervention Types: Drug
Placebo Oil
Drug
PlaceboComparator Group · 1 Intervention: Cannabis · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Medical Cannabis
Not yet FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 16-48 days; 90 minutes after each dose

Who is running the clinical trial?

Pippa HawleyLead Sponsor
1 Previous Clinical Trials
176 Total Patients Enrolled
Philippa Hawley, FRCPCPrincipal InvestigatorBC Cancer
1 Previous Clinical Trials
70 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 25th, 2021

Last Reviewed: November 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.